The consumption of a high-fat, high-sucrose diet (HFHSD) promotes obesity. Although dietary sugars are obesogenic, they activates a negative feedback mechanism between hepatic fibroblast growth factor 21 (FGF21) and oxytocin neurons in the paraventricular nucleus of the hypothalamus (PVHOxt), thereby suppressing sugar appetite. We previously reported that the low-calorie rare sugars D-allulose, D-tagatose, and D-sorbitol induce FGF21, activate PVHOxt neurons, and reduce sugar intake. In this study, we evaluated the anti-obesity effects of these rare sugars in male BL/6 mice. The mice were fed with HFHSD, along with ad libitum access to FGF21-inducing rare sugar solutions for 1 month. Body weight, feed intake, fluid intake, and total caloric intake were recorded every 3 days. At the end of the treatment, obesity-associated parameters- including insulin resistance, glucose intolerance, and adiposity-were assessed. Rare sugar supplementation reduced body weight gain and total caloric intake without increasing energy expenditure. These interventions improved obesity-associated phenotypes to varying degrees, suggesting that these rare sugars ameliorated the overall state of diet-induced obesity. In contrast, these sugars did not reverse established obesity or insulin resistance, as prolonged HFHSD feeding desensitized mice to their effects. Therefore, rare sugars appear effective for the prevention, but not the treatment, of diet-induced obesity.

OBJECTIVES:While glucagon raises blood glucose levels, it also promotes lipolysis and energy expenditure, and suppresses food intake and gastrointestinal motility, thereby resulting in weight loss. We previously reported that sodium-glucose cotransporter 1 (SGLT1) is highly expressed in pancreatic α cells. The present study aimed to investigate the effects of α-methyl d-glucopyranoside (αMG), an SGLT-specific substrate, on endogenous glucagon secretion and metabolic parameters in obese diabetic mice. METHODS:We injected αMG intraperitoneally daily into high fat, high sucrose diet (HFHSD)-fed mice and db/db mice, and measured metabolic parameters including plasma glucagon concentration. During the treatment with αMG, we evaluated various metabolic conditions, such as body weight, glucose tolerance and hepatic steatosis, in these mice. We also used SGLT1-specific inhibitor and liver-specific glucagon receptor knockout mice to elucidate the underlying mechanism. RESULTS:We showed that αMG stimulates endogenous glucagon secretion, and that chronic injection of αMG led to dramatic weight loss, improved glucose intolerance, and ameliorated hepatic steatosis, by reducing food intake and increasing energy expenditure and fat utilization, among obese diabetic mice. Interestingly amelioration of hepatic steatosis was abolished in liver-specific glucagon receptor knockout mice, but body weight reduction was not abolished. In addition, αMG, although to a modest extent, distinctly enhanced urinary glucose excretion. CONCLUSIONS:These results in this study suggest that αMG stimulates endogenous glucagon secretion and may lead to a therapeutic strategy for obesity-associated metabolic diseases.

Feeding behavior is controlled by various neural networks in the brain that are involved in different feeding phases: Food procurement, consumption, and termination. However, the specific neural circuits controlling the food consumption phase remain poorly understood. Here, we investigated the roles of dopaminergic neurons in the paraventricular nucleus of the hypothalamus (PVH) in the feeding behavior in mice. Our results indicated that the PVH dopaminergic neurons were critical for extending the food consumption phase and involved in the development of obesity through epigenetic mechanisms. These neurons synchronized with proopiomelanocortin neurons during consumption, were stimulated by proopiomelanocortin activation, and projected to the lateral habenula (LHb), where dopamine receptor D2 was involved in the increase in food consumption. In addition, upregulated tyrosine hydroxylase (TH) expression in PVH was associated with obesity and indispensable for obesity induction in mice lacking Dnmt3a. Taken together, our results highlight the roles of PVH dopaminergic neurons in promoting food consumption and obesity induction.

Mammals adaptively regulate energy metabolism in response to environmental changes such as starvation and cold circumstances. Thioredoxin-interacting protein (Txnip), known as a redox regulator, serves as a nutrient sensor regulating energy homeostasis. Txnip is essential for mice to adapt to starvation, but its role in adapting to cold circumstances remains unclear. Here, we identified Txnip as a pivotal factor for maintaining non-shivering thermogenesis in mice. Txnip protein levels in brown adipose tissue (BAT) were upregulated by the acute cold exposure. Txnip-deficient (Txnip-/-) mice acclimated to thermoneutrality (30°C) exhibited significant BAT enlargement and triglyceride accumulation with downregulation of BAT signature and metabolic gene expression. Upon acute cold exposure (5°C), Txnip-/- mice showed a rapid decline in BAT surface temperatures with the failure of increasing metabolic respiration, developing lethal hypothermia. The BAT dysfunction and cold susceptibility in Txnip-/- mice were corrected by acclimation to 16°C, protecting the mice from life-threatening hypothermia. Transcriptomic and metabolomic analysis using dissected BAT revealed that despite preserving glycolysis, the BAT of Txnip-/- mice failed to activate the catabolism of branched-chain amino acids and fatty acids in response to acute cold stress. These findings illustrate that Txnip is required for maintaining basal BAT function and ensuring cold-induced thermogenesis.

N6-methyladenosine (m6A) is an abundant chemical RNA modification involved in the regulation of many biological processes. The m6A demethylase FTO (fat mass and obesity-associated protein) is known to affect body weight, but its systemic context and underlying mechanisms remain unclear. Here, we found that mice lacking or overexpressing Fto in agouti-related peptide-expressing (AgRP) neurons in the hypothalamus exhibited decreased and increased body weight, respectively. FTO demethylated m6A on mRNAs for proteins associated with membrane trafficking and alternative splicing in AgRP neurons. Downstream, FTO-modulated alternative splicing of the axonal motor protein Kif1a affected its hinge region, which is relevant to the structure and function of KIF1A. Notably, Kif1a knockdown in AgRP neurons suppressed the weight gain of mice overexpressing Fto. In addition, FTO increased the trafficking and secretion of dense-core vesicles containing neuropeptides NPY and AgRP from AgRP neurons. Collectively, these results reveal a novel regulatory FTO-KIF1A axis in the brain affecting appetite-stimulating AgRP neurons and systemic energy homeostasis, via FTO regulation of the epitranscriptome of AgRP neurons.

There is currently a global epidemic of obesity and obesity-related diseases such as type 2 diabetes due to decreased physical activity, excessive food intake, and/or genetic predisposition. The Hippo-YAP1 pathway has attracted attention as a potential therapeutic target because YAP1/TAZ activation in murine immature adipocytes in vitro suppresses their differentiation by inhibiting PPARγ activity. However, the role of YAP1 activation in mature adipocytes in vivo remains unclear. MOB1, whose expression is increased in obesity, is the hub of the Hippo core molecule complex and negatively regulates YAP1/TAZ activation. Therefore, we generated aMob1DKO mutant mice, which feature deficiency of Mob1a/b specifically in mature adipocytes. Compared to controls, aMob1DKO mice subjected to a high-fat diet showed beneficial changes consistent with resistance to diet-induced obesity. The mutants exhibited increases in basal lipolysis, "beiging," and energy expenditure, as well as suppression of ROS production and inflammation in white adipose tissue. Insulin sensitivity and glucose tolerance were improved, and ectopic fat accumulation was reduced. Most of these changes were dependent on the YAP1 activation observed in mature white adipose tissue of aMob1DKO mice. FGF21, which improves lipid metabolism, was upregulated directly via YAP1 activation, and many of the phenotypes seen in aMob1DKO mice were also dependent on FGF21. Thus, the aMob1DKO mouse is an interesting model for the study of the metabolic effects of diet-induced obesity and protection against diabetes. Our work suggests that a YAP1-FGF21 axis exists in adipocytes that may be a potential therapeutic target for obesity.

Obesity rates have been increasing worldwide for decades, mainly due to environmental factors, such as diet, nutrition, and exercise. However, the molecular mechanisms through which environmental factors induce obesity remain unclear. Several mechanisms underlie the body's response to environmental factors, and one of the main mechanisms involves epigenetic modifications, such as DNA methylation. The pattern of DNA methylation is influenced by environmental factors, and altered DNA methylation patterns can affect gene expression profiles and phenotypes. DNA methylation may mediate the development of obesity caused by environmental factors. Similar to the factors governing obesity, DNA methylation is influenced by nutrients and metabolites. Notably, DNA methylation is associated with body size and weight programming. The DNA methylation levels of proopiomelanocortin (Pomc) and neuropeptide Y (Npy) in the hypothalamic feeding center, a key region controlling systemic energy balance, are affected by diet. Conditional knockout mouse studies of epigenetic enzymes have shown that DNA methylation in the hypothalamic feeding center plays an indispensable role in energy homeostasis. In this review, we discuss the role of DNA methylation in the hypothalamic feeding center as a potential mechanism underlying the development of obesity induced by environmental factors.

The pathophysiology of type 2 diabetes involves insulin and glucagon. Protein kinase C (Pkc)-δ, a serine–threonine kinase, is ubiquitously expressed and involved in regulating cell death and proliferation. However, the role of Pkcδ in regulating glucagon secretion in pancreatic α-cells remains unclear. Therefore, this study aimed to elucidate the physiological role of Pkcδ in glucagon secretion from pancreatic α-cells. Glucagon secretions were investigated in Pkcδ-knockdown InR1G9 cells and pancreatic α-cell-specific Pkcδ-knockout (αPkcδKO) mice. Knockdown of Pkcδ in the glucagon-secreting cell line InR1G9 cells reduced glucagon secretion. The basic amino acid arginine enhances glucagon secretion via voltage-dependent calcium channels (VDCC). Furthermore, we showed that arginine increased Pkcδ phosphorylation at Thr505, which is critical for Pkcδ activation. Interestingly, the knockdown of Pkcδ in InR1G9 cells reduced arginine-induced glucagon secretion. Moreover, arginine-induced glucagon secretions were decreased in αPkcδKO mice and islets from αPkcδKO mice. Pkcδ is essential for arginine-induced glucagon secretion in pancreatic α-cells. Therefore, this study may contribute to the elucidation of the molecular mechanism of amino acid-induced glucagon secretion and the development of novel antidiabetic drugs targeting Pkcδ and glucagon.

Abstract Objectives Thyrotropin-releasing hormone (TRH) was the first hypothalamic hormone isolated that stimulates pituitary thyroid-stimulating hormone (TSH) secretion. TRH was later found to be distributed throughout the brain, gastrointestinal tract and pancreaticβ-cells. We previously reported the TRH null mice (conventional TRHKO) which exhibit characteristic tertiary hypothyroidism, however the responsible regionfor the hypothalamic-pituitary-thyroid (HPT) axis remained obscure because of the broad expression of TRH in hypothalamus. Previous studies suggested that TRH in the hypothalamic paraventricular nucleus (PVN) was secreted through the median eminence (ME), however it was not directly demonstrated . To determine the region functionally responsible for the HPT axis, we established and analyzed PVN-specific TRH knock-out (PVN-TRHKO) mice. Methods For the targeting vector, a Neo-loxP cassette was inserted into the 3′-UTR of the Trh gene in ES cells. Another loxP site was placed at intron 1. After we obtained the Trh +/lox [neo+] founder mice, we crossed them with the CAG-FLPe transgenic mice to remove the Neo cassette. The offspring were backcrossed to wild-type mice, producing conditional knock-out mice without the Neo cassette, which were labeled as Trh +/lox . We crossed Trh +/lox with transgenic mice expressing Single-minded homolog (Sim)1-Cre recombinase and created PVN-TRHKO mice (Sim1-Cre; Trh lox/lox mice). We confirmed that most Sim1 was expressed in the PVN using Sim1-Cre/tdTomato mice. We performed the following experiments using PVN-TRHKO andTrh lox/lox mice as control (Ct). 1) immunostaining of TRH using antibody forproTRH in cerebrum, 2)qPCR analysis detecting the expression of preproTrh mRNA in hypothalamic PVN, 3) measurement of the level of serum free-T4 and TSH, 4)qPCR analysis detecting theexpression levels of Tshβ, Prl, Cga, Gh, Pomc and Lhβ gene mRNAin the anterior pituitary and 5)immunohistochemical analysis with antibodies for TSHβ and Prolactin in anterior pituitary. Results In the PVN-TRHKO mice, 1) ProTRH-immunopositive cells were lost in the area of PVN and ME, whereas proTRH detected in the medial preoptic area(MPA) and medial preoptic nucleus (MPO) in the hypothalamus.2)The expression level of proTRHmRNA was decreased to7.7% compared with Ct.3) Free-T4 levels decreased to 50% and the TSH levels increased to 170% of those in Ct. 4) TshβmRNA levels were decreased by 65% and thePrlmRNA levels were reduced to 55% of those in Ct. 5) The number of TSH-positive andProlactin-positive cells in the pituitary significantly decreased to 50% and 60% of those in Ct. Conclusions PVN-TRHKO mice exhibited tertiary hypothyroidism similar to conventional TRHKO. The pathway of TRH neuron from PVN to ME was lost in the PVN-TRHKO mice. These findings are conclusive evidence that the TRH neuron in the PVN is the center of the HPT axis. Presentation: No date and time listed

Background: Thyrotropin-releasing hormone (TRH) was the first hypothalamic hormone isolated that stimulates pituitary thyrotropin (TSH) secretion. TRH was also later found to be a stimulator of pituitary prolactin and distributed throughout the brain, gastrointestinal tract, and pancreatic beta cells. We previously reported the development of TRH null mice (conventional TRHKO), which exhibit characteristic tertiary hypothyroidism and impaired glucose tolerance due to insufficient insulin secretion. Although in the past five decades many investigators, us included, have attempted to determine the hypothalamic nucleus responsible for the hypothalamic-pituitary-thyroid (HPT) axis, it remained obscure because of the broad expression of TRH.Methods: To determine the hypothalamic region functionally responsible for the HPT axis, we established paraventricular nucleus (PVN)-specific TRH knockout (PVN-TRHKO) mice by mating Trh floxed mice and single-minded homolog 1 (Sim1)-Cre transgenic mice. We originally confirmed that most Sim1 was expressed in the PVN using Sim1-Cre/tdTomato mice.Results: These PVN-TRHKO mice exhibited tertiary hypothyroidism similar to conventional TRHKO mice; however, they did not show the impaired glucose tolerance observed in the latter, suggesting that TRH from non-PVN sources is essential for glucose regulation. In addition, a severe reduction in prolactin expression was observed in the pituitary of PVN-TRHKO mice compared with that in TRHKO mice.Conclusions: These findings are conclusive evidence that the PVN is the center of the HPT axis for regulation of serum levels of thyroid hormones and that the serum TSH levels are not decreased in tertiary hypothyroidism. We also noted that TRH from the PVN regulated prolactin, whereas TRH from non-PVN sources regulated glucose metabolism.

Phosphatidylinositol 3-kinase (PI3K) plays an important role in protein metabolism and cell growth. We here show that mice (M-PDK1KO mice) with skeletal muscle–specific deficiency of 3′-phosphoinositide–dependent kinase 1 (PDK1), a key component of PI3K signaling pathway, manifest a reduced skeletal muscle mass under the static condition as well as impairment of mechanical load–induced muscle hypertrophy. Whereas mechanical load-induced changes in gene expression were not affected, the phosphorylation of ribosomal protein S6 kinase (S6K) and S6 induced by mechanical load was attenuated in skeletal muscle of M-PDK1KO mice, suggesting that PDK1 regulates muscle hypertrophy not through changes in gene expression but through stimulation of kinase cascades such as the S6K-S6 axis, which plays a key role in protein synthesis. Administration of the β 2 -adrenergic receptor (AR) agonist clenbuterol activated the S6K-S6 axis in skeletal muscle and induced muscle hypertrophy in mice. These effects of clenbuterol were attenuated in M-PDK1KO mice, and mechanical load–induced activation of the S6K-S6 axis and muscle hypertrophy were inhibited in mice with skeletal muscle–specific deficiency of β 2 -AR. Our results suggest that PDK1 regulates skeletal muscle mass under the static condition and that it contributes to mechanical load–induced muscle hypertrophy, at least in part by mediating signaling from β 2 -AR.

Dysregulation of glucagon is associated with the pathophysiology of type 2 diabetes. We previously reported that postprandial hyperglucagonemia is more obvious than fasting hyperglucagonemia in type 2 diabetes patients. However, which nutrient stimulates glucagon secretion in the diabetic state and the underlying mechanism after nutrient intake are unclear. To answer these questions, we measured plasma glucagon levels in diabetic mice after oral administration of various nutrients. The effects of nutrients on glucagon secretion were assessed using islets isolated from diabetic mice and palmitate-treated islets. In addition, we analyzed the expression levels of branched chain amino acid (BCAA) catabolism-related enzymes and their metabolites in diabetic islets. We found that protein, but not carbohydrate or lipid, increased plasma glucagon levels in diabetic mice. Among amino acids, BCAAs, but not the other essential or nonessential amino acids, increased plasma glucagon levels. BCAAs also directly increased the intracellular calcium concentration in α cells. When BCAAs transport was suppressed by an inhibitor of system L-amino acid transporters, glucagon secretion was reduced even in the presence of BCAAs. We also found that the expression levels of BCAA catabolism-related enzymes and their metabolite contents were altered in diabetic islets and palmitate-treated islets compared to control islets, indicating disordered BCAA catabolism in diabetic islets. Furthermore, BCKDK inhibitor BT2 suppressed BCAA-induced hypersecretion of glucagon in diabetic islets and palmitate-treated islets. Taken together, postprandial hypersecretion of glucagon in the diabetic state is attributable to disordered BCAA catabolism in pancreatic islet cells.

Obesity is a major risk factors for type 2 diabetes, and weight loss is beneficial to diabetic patients who are obese or overweight. Dipeptidyl peptidase-4 (DPP-4) inhibitors are anti-diabetic drugs. Although it has been known that the effect of most of the DPP-4 inhibitors on body weight is neutral, several studies suggested that some DPP-4 inhibitors suppressed body weight. Nonetheless, the mechanisms underlying DPP-4 inhibitor-induced weight loss are not fully understood. In this study, the mice fed high-fat high sucrose diet (HFHSD) containing a DPP4 inhibitor, anagliptin, showed reduced food intake and body weight compared to the mice fed non-treated HFHSD, but oxygen consumption and respiratory exchange ratio (RER) were not altered. Sequential administration of leptin suppressed food intake and body weight more apparently in anagliptin treated HFHSD fed mice than non-treated HFHSD fed mice. Oxygen consumption and RER were comparable between anagliptin treated and non-treated mice after leptin administration. The number of phospho STAT3 expressed cells in the arcuate nucleus after leptin administration was increased in anagliptin treated mice compared to non-treated mice. These data suggested that anagliptin ameliorated leptin resistance induced by HFHSD and thereby decreased food intake and body weight. These effects of anagliptin could be beneficial to the treatment of obese diabetic patients.

Background: Circulating plasma glucagon level is known to increase in diabetic state. We found that postprandial plasma glucagon level significantly increased in diabetic mice more than that in the control group. However, it’s still unknown which nutrient stimulates glucagon secretion as well as the underlying mechanism of glucagon secretion enhancement in diabetic state. Therefore, we aimed to answer these questions by using diabetic mouse models and isolated islets. Methods: Plasma glucagon levels were measured by sandwich ELISA in several diabetic model mice after oral administration of various nutrients. The effects of nutrients on glucagon secretion were assessed using isolated islets from diabetic mice. The expression levels of nutrient catabolism-related factors were analyzed in diabetic mice compared with control mice. Results and Discussions: Rather than carbohydrate or lipid, protein increased plasma glucagon levels in all diabetic models including high-fat diet mice, STZ mice, and db/db mice. Among amino acids, branched-chain amino acids (BCAA), but not the other essential or nonessential amino acids, increased plasma glucagon. BCAA directly stimulated glucagon secretion in isolated islets from diabetic mice, which was suppressed by amino acid transporter inhibitor (BCH) or branched-chain alpha-ketoacid dehydrogenase (BCKDK) inhibitor (BT2). This suggests that BCAA’s stimulation of glucagon secretion is mediated by BCAA catabolism in alpha cells. We also found that the expression level of BCKDK was higher, while branched-chain amino acid transaminase 2 (BCAT2) was lower, in diabetic islets than control islets. Considering that dysfunction of BCAA catabolism has been reported in both adipocytes and hepatocytes of diabetic mice, the dysfunction of BCAA catabolism might be a common pathogenesis for metabolic disorders observed in diabetes. Disclosure E. Wada: None. M. Kobayashi: None. O. Kikuchi: None. D. Kohno: None. T. Kitamura: None.

Obesity is a health problem worldwide, and brown adipose tissue (BAT) is important for energy expenditure. Here, we explored the role of leukotriene A4 hydrolase (LTA4 H), a key enzyme in the synthesis of the lipid mediator leukotriene B4 (LTB4 ), in diet-induced obesity. LTA4 H-deficient (LTA4 H-KO) mice fed a high-fat diet (HFD) showed a lean phenotype, and bone-marrow transplantation studies revealed that LTA4 H-deficiency in non-hematopoietic cells was responsible for this lean phenotype. LTA4 H-KO mice exhibited greater energy expenditure, but similar food intake and fecal energy loss. LTA4 H-KO BAT showed higher expression of thermogenesis-related genes. In addition, the plasma thyroid-stimulating hormone and thyroid hormone concentrations, as well as HFD-induced catecholamine secretion, were higher in LTA4 H-KO mice. In contrast, LTB4 receptor (BLT1)-deficient mice did not show a lean phenotype, implying that the phenotype of LTA4 H-KO mice is independent of the LTB4 /BLT1 axis. These results indicate that LTA4 H mediates the diet-induced obesity by reducing catecholamine and thyroid hormone secretion.

Phosphoinositide 3-kinase (PI3K) signaling in hypothalamic neurons integrates peripheral metabolic cues, including leptin and insulin, to coordinate systemic glucose and energy homeostasis. PI3K is composed of different subunits, each of which has several unique isoforms. However, the role of the PI3K subunits and isoforms in the ventromedial hypothalamus (VMH), a prominent site for the regulation of glucose and energy homeostasis, is unclear. Here we investigated the role of subunit p110β in steroidogenic factor-1 (SF-1) neurons of the VMH in the regulation of metabolism. Our data demonstrate that the deletion of p110β in SF-1 neurons disrupts glucose metabolism, rendering the mice insulin resistant. In addition, the deletion of p110β in SF-1 neurons leads to the whitening of brown adipose tissues and increased susceptibility to diet-induced obesity due to blunted energy expenditure. These results highlight a critical role for p110β in the regulation of glucose and energy homeostasis via VMH neurons.

A recent report described that sodium glucose cotransporter (SGLT) 1 and 2 were expressed in α cells, and dapagliflozin which is a specific SGLT2 inhibitor, increased plasma glucagon levels by inhibiting SGLT2 in α cells. However, it is still controversial whether SGLT2 inhibitors increase plasma glucagon levels in vivo . Here, we showed that dapagliflozin, but not canagliflozin which is a SGLT2/low-potency-SGLT1 inhibitor, increased plasma glucagon levels in mice fed a high-fat, high-sucrose diet (HFHSD) and diabetic db/db mice. A glucose clamp study revealed that the plasma glucagon increase associated with dapagliflozin could be explained as a response to acute declines in blood glucose. RT-PCR and whole RNA sequencing revealed that SGLT1 and glucose transporter 1 (GLUT1), but not SGLT2, were expressed in αTC1 cells and mouse islets. We showed that canagliflozin suppressed glucagon secretion by inhibiting SGLT1 in α cells; consequently, plasma glucagon did not increase with canagliflozin, even though blood glucose declined. We also showed that the SGLT1 effect on glucagon secretion depended on sodium/glucose cotransport, but not on metabolic effect of glucose. Islets from HFHSD and db/db mice displayed higher SGLT1 expression and lower GLUT1 expression than the islets from control mice. These expression levels were associated with glucagon secretion levels. Furthermore, SGLT1 inhibitor and siRNA against SGLT1 suppressed glucagon secretion in isolated islets. These data suggested that a novel mechanism regulated glucagon secretion, through SGLT1, in α cells. This finding explained the distinct effects of dapagliflozin and canagliflozin on plasma glucagon levels in mice. Disclosure T. Suga: None. O. Kikuchi: None. M. Kobayashi: None. S. Matsui: None. H.H. Hashimoto: None. T. Sasaki: None. S. Kakizaki: None. M. Yamada: None. T. Kitamura: None.

Maternal malnutrition, which causes prenatal exposure to excessive glucocorticoid, induces adverse metabolic programming, leading to hypertension in offspring. In offspring of pregnant rats receiving a low-protein diet or dexamethasone, a synthetic glucocorticoid, mRNA expression of angiotensin receptor type 1a (Agtr1a) in the paraventricular nucleus (PVN) of the hypothalamus was upregulated, concurrent with reduced expression of DNA methyltransferase 3a (Dnmt3a), reduced binding of DNMT3a to the Agtr1a gene, and DNA demethylation. Salt loading increased BP in both types of offspring, suggesting that elevated hypothalamic Agtr1a expression is epigenetically modulated by excessive glucocorticoid and leads to adult-onset salt-sensitive hypertension. Consistent with this, dexamethasone treatment of PVN cells upregulated Agtr1a, while downregulating Dnmt3a, and decreased DNMT3a binding and DNA demethylation at the Agtr1a locus. In addition, Dnmt3a knockdown upregulated Agtr1a independently of dexamethasone. Hypothalamic neuron-specific Dnmt3a-deficient mice exhibited upregulation of Agtr1a in the PVN and salt-induced BP elevation without dexamethasone treatment. By contrast, dexamethasone-treated Agtr1a-deficient mice failed to show salt-induced BP elevation, despite reduced expression of Dnmt3a. Thus, epigenetic modulation of hypothalamic angiotensin signaling contributes to salt-sensitive hypertension induced by prenatal glucocorticoid excess in offspring of mothers that are malnourished during pregnancy.

Diet affects health through ingested calories and macronutrients, and macronutrient balance affects health span. The mechanisms regulating macronutrient-based diet choices are poorly understood. Previous studies had shown that NAD-dependent deacetylase sirtuin-1 (SIRT1) in part influences the health-promoting effects of caloric restriction by boosting fat use in peripheral tissues. Here, we show that neuronal SIRT1 shifts diet choice from sucrose to fat in mice, matching the peripheral metabolic shift. SIRT1-mediated suppression of simple sugar preference requires oxytocin signalling, and SIRT1 in oxytocin neurons drives this effect. The hepatokine FGF21 acts as an endocrine signal to oxytocin neurons, promoting neuronal activation and Oxt transcription and suppressing the simple sugar preference. SIRT1 promotes FGF21 signalling in oxytocin neurons and stimulates Oxt transcription through NRF2. Thus, neuronal SIRT1 contributes to the homeostatic regulation of macronutrient-based diet selection in mice.